Whole-exome sequencing to identify novel somatic mutations in squamous cell lung cancers.
暂无分享,去创建一个
Zhao-Hui Gu | Zhao-hui Gu | C. Pan | Chun-Ming Pan | B. Han | Huan-ying Wan | Bing Han | Yi Xiang | Cui-Xia Zheng | Rong-Xin Zhang | Xia-Jun Rong | Xia Chen | Qing-Yun Li | Huan-Ying Wan | Xia-Jun Rong | Y. Xiang | Xia Chen | Cuixia Zheng | Rong-xin Zhang | Qing-yun Li | Chun-ming Pan | Qing-yun Li
[1] F. Westermann,et al. Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance. , 2011, Cancer research.
[2] B. Howard,et al. The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.
[3] D. Livingston,et al. Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.
[4] P. Hainaut,et al. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. , 2010, Carcinogenesis.
[5] A. Borczuk,et al. Genomics of lung cancer. , 2009, Proceedings of the American Thoracic Society.
[6] J. Espinosa,et al. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. , 2001, Molecular cell.
[7] Tsutomu Ohta,et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy , 2008, Proceedings of the National Academy of Sciences.
[8] Jukka-Pekka Mecklin,et al. Somatic mutations and germline sequence variants in patients with familial colorectal cancer , 2010, International journal of cancer.
[9] D. Livingston,et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.
[10] I. Petersen,et al. Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.
[11] P Baas,et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] D. Livingston,et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation , 1998, Nature.
[13] Y. Yatabe,et al. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib , 2007, British Journal of Cancer.
[14] Robert Gentleman,et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.
[15] Torsten Schwede,et al. BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .
[16] Steven Henikoff,et al. SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..
[17] D. Ettinger,et al. Metastatic non-small cell lung cancer , 1993 .
[18] Angela N. Brooks,et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.
[19] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Meyerson,et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. , 2011, Cancer discovery.
[21] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[22] J. Kutok,et al. Human HTm4 is a hematopoietic cell cycle regulator. , 2002, The Journal of clinical investigation.
[23] K. Cibulskis,et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.
[24] M. Meyerson,et al. Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.
[25] M. Ladanyi,et al. Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.
[26] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[27] Niruthika Sritharan,et al. Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.
[28] Levi A Garraway,et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. , 2007, Cancer research.
[29] D. Livingston,et al. Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.
[30] K. Gardner,et al. Recruitment of p300/CBP in p53-Dependent Signal Pathways , 1997, Cell.
[31] J. Kutok,et al. Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues , 2009, Journal of cellular and molecular medicine.
[32] H. Ozçelik,et al. Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines , 2011, BMC Medical Genomics.
[33] Raffaella Faraoni,et al. CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity , 2012, Molecular Cancer Therapeutics.
[34] David Newsome,et al. Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.
[35] A. McCullough. Comprehensive genomic characterization of squamous cell lung cancers , 2013 .